UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 29, 2016
AMARANTUS
BIOSCIENCE HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-55016 |
|
26-0690857 |
(State
or other jurisdiction
of incorporation or organization) |
|
(Commission
File Number) |
|
IRS
Employer
Identification
No.) |
655
Montgomery Street, Suite 900
San
Francisco, CA |
|
94111 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
(408)
737-2734
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On
January 29, 2016, Amarantus Bioscience Holdings, Inc. (the “Company”) issued a press release announcing the
issuance of Chinese patent number ZL2009801163060 entitled “Neurodegenerative Disorders” covering
the use of MANF for the treatment of Parkinson’s disease and other neurodegenerative conditions.
A
copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 |
Financial Statements and Exhibits. |
(d)
Exhibits
Exhibit
No. |
|
Description |
|
|
|
99.1 |
|
Amarantus
Bioscience Holdings, Inc. Press Release, dated January 29, 2016. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
AMARANTUS
BIOSCIENCE HOLDINGS, INC. |
|
|
|
Date:
January 29, 2016 |
By: |
/s/
Gerald E. Commissiong |
|
|
Name:
Gerald E. Commissiong |
|
|
Title:
Chief Executive Officer |
3
Exhibit 99.1
Amarantus
Announces Issuance of Chinese Patent Covering Use of MANF for the
Treatment of Parkinson’s Disease
-
Patent issuance will provide intellectual property protection in China for protein therapy,
gene therapy and cell therapy applications
of MANF -
SAN
FRANCISCO, CA – January 29, 2016 – Amarantus Bioscience Holdings,
Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases,
today announced the issuance of Chinese patent number ZL2009801163060 entitled
“Neurodegenerative Disorders” covering the use of MANF for the treatment of
Parkinson’s disease and other neurodegenerative conditions. The claims issued extend patent coverage for MANF protein
therapy, gene therapy and cell therapy applications into 2029.
“The
Chinese market represents a potential significant market opportunity for Amarantus,” said Gerald E. Commissiong, President
& CEO of Amarantus. “MANF has demonstrated proof of concept in various efficacy and delivery animal models of Parkinson’s
disease. Going forward, the Company will look to partner the development of MANF with a group in China capable of bringing this
technology to market in that region.”
The
key claim issued in this patent is “Use of MANF for the manufacture of a medicament for administration to the substantia
nigra region of the brain for treating Parkinson’s disease.” The substantia nigra is a key area of the brain where
dopamine producing neurons degenerate in Parkinson’s disease. Additional claims covering combinations of MANF and other
therapeutic moieties were also granted. This patent adds to Amarantus’ extensive international intellectual property portfolio
covering compositions of matter, methods of use and formulations for MANF.
About Mesencephalic-Astrocyte-derived Neurotrophic
Factor (MANF)
MANF
(mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring
protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease,
via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative
medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder
of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's
lead indications are retinitis pigmentosa (RP) and retinal artery occlusion (RAO), and additional indications including Parkinson's
disease, diabetes, and Wolfram's syndrome are currently being evaluated. Further applications for MANF may include Alzheimer's
disease, traumatic brain injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases
currently under consideration.
About
Amarantus BioScience Holdings, Inc.
Amarantus
BioScience Holdings (OTCQX:AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of
regenerative medicine neurology, and orphan diseases. The Company has an exclusive worldwide license to intellectual property
rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product
in development for the treatment of adult severe burns currently preparing to enter Phase 2 clinical studies. The Company is currently
evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to
support clinical development expansion into those areas. AMBS also has development rights to eltoprazine, a small molecule currently
in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia, with the potential to expand into adult ADHD
and Alzheimer's aggression. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived
neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa
(RP) and retinal artery occlusion (RAO). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that
led to MANF's discovery.
AMBS'
Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for
the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive
worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed
by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's
disease (NuroPro).
For
further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter
and Google+.
Forward-Looking
Statements
Certain
statements, other than purely historical information, including estimates, projections, statements relating to our business plans,
objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements.
These forward-looking statements generally are identified by the words "believes," "project," "expects,"
"anticipates," "estimates," "intends," "strategy," "plan," "may,"
"will," "would," "will be," "will continue," "will likely result," and similar
expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties
which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the
actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our
operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory
changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties
should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
Investor
and Media Contact:
Ascendant
Partners, LLC
Fred
Sommer
732-410-9810
fred@ascendantpartnersllc.com
Source:
Amarantus Bioscience Holdings, Inc.
###
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024